The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia

Endotoxemia Clinical Trial

— SALYCENDO  

Official title:

The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02922673
• Other study ID #: SALYCENDO
• Secondary ID: 2016-001971-61NL
• Status: Completed
• Phase: N/A
• Start date: September 2016
• Est. completion date: September 2017

Study information

• Verified date: September 2016
• Source: Radboud University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale:

The last years, research focus has moved to immunostimulatory agents in order to restore or increase the functionality of the immune system during sepsis-induced immunoparalysis. Epidemiologic data show that prehospital use of low dose acetylsalicylic acid (ASA) is associated with improved outcome of sepsis. Experimental data indicate that ASA exerts pro-inflammatory effects during systemic inflammation. However, it remains to be determined whether treatment with ASA improves immune function once immunoparalysis has developed and whether prehospital use of low dose ASA prevents the development of immunoparalysis. In the former case, ASA is a potential immunostimulatory therapy that can treat sepsis-induced immunoparalysis. In the latter case, ASA may have a broader indication as an immunomodulating agent. Taken together, ASA might be a promising, cheap, well-known, and globally available agent to reduce the incidence of secondary infections and improve patient outcome in sepsis.

Objective:

• To determine whether acetylsalicylic acid treatment can reverse endotoxin tolerance, which is expressed as a decrease in pro-inflammatory cytokine levels between the first and second endotoxin challenge.

• To determine whether acetylsalicylic acid prophylaxis can prevent endotoxin tolerance, which is expressed as a decrease in pro-inflammatory cytokine levels between the first and second endotoxin challenge.

Study design:

Double-blind randomized placebo-controlled pilot study in 30 healthy male volunteers during repeated experimental endotoxemia. All subjects will receive a 14 day course of study medication (low-dose ASA or placebo) and undergo experimental endotoxemia (lipopolysacharide (LPS), E.Coli type O113) on day 7 and on day 14. LPS is administrated using an initial bolus of 1ng/kg followed by continuous infusion at 1ng/kg/hr during 3 hours.

Subjects are randomized in three study arms:

1. Treatment group: 7 days placebo / first endotoxemia / 7 days ASA 80 mg (loading dose on first day of 160mg) / second endotoxemia

2. Prophylaxis group: 7 days ASA 80 mg (loading dose on first day of 160mg) / first endotoxemia / 7 days ASA 80 mg / second endotoxemia

3. Placebo group: 7 days placebo / first endotoxemia / 7 days placebo / second endotoxemia

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: September 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Written informed consent

• Age =18 and =35 yrs

• Male

• Healthy (as confirmed by medical history, examination, ECG, blood sampling)

Exclusion Criteria:

• Use of any medication

• Use of COX-inhibitors within 6 weeks prior to the first endotoxemia day

• Smoking

• Known anaphylaxis or hypersensitivity to acetylsalicylic acid or non-investigational products

• History or signs of atopic syndrome (asthma, rhinitis with medication and/or eczema)

• History of peptic ulcer disease

• History or signs of hematological disease

• Thrombocytopenia (<150*10^9/ml) or anemia (hemoglobin < 8.0 mmol/L)

• History of glucose-6-phosphate dehydrogenase deficiency

• History of intracranial hemorrhage

• History, signs or symptoms of cardiovascular disease, in particular:

• Previous spontaneous vagal collapse

• History of atrial or ventricular arrhythmia

• Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complete left bundle branch block

• Hypertension (defined as RR systolic > 160 or RR diastolic > 90)

• Hypotension (defined as RR systolic < 100 or RR diastolic < 50)

• Renal impairment (defined as plasma creatinine >120 µmol/l)

• Liver enzyme abnormalities (above 2x the upper limit of normal)

• Medical history of any disease associated with immune deficiency

• CRP > 20 mg/L, WBC > 12x109/L or < 4 x109/L or clinically significant acute illness, including infections, within 4 weeks before the first endotoxemia day

• Previous (participation in a study with) LPS administration

• Participation in a drug trial or donation of blood 3 months prior to first endotoxemia day

• Any vaccination within 3 months prior to first endotoxemia day until the end of the study

• Recent hospital admission or surgery with general anesthesia (<3 months to endotoxemia day)

• Use of recreational drugs within 21 days prior to the first endotoxemia day

• Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study

Related Conditions & MeSH terms

• Endotoxemia

Intervention

Drug:
• Aspirin

• Placebo

Locations

Country	Name	City	State
Netherlands	Intensive Care Medicine, Radboud University Nijmegen Medical Centre	Nijmegen	Gelderland

Sponsors (1)

Lead Sponsor	Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in concentration plasma TNFalpha (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in concentration plasma IL-6 (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in concentration plasma IL-8 (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in plasma concentration of IL-10 (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in plasma concentration of IL-1RA (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in plasma concentration of IL-1beta (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in plasma concentration of MCP-1 (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge
Secondary	Change in plasma concentration of MIP-1alpha (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in plasma concentration of MIP-1beta (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in monocytic HLA-DR expression (mHLA-DR)		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in symptoms during endotoxin day		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in blood pressure		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in temperature		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in heart rate		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in cerebral blood flow using Transcranial Doppler (TCD) measurements and Near Infrared Spectroscopy (NIRS)		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Arterial bloodgas		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in platelet monocyte complexes		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in monocyte surface antigen expression of PD-L1		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Thromboxane B2		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Prostaglandin E2 (PGE-M)		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in plasma enkephalin		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Kidney damage markers in urine (NGAL, KIM-1 and L-FABP)		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in leukocyte count (and differentiation)		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in transcriptional activity of leukocytes		Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in plasma concentration of IFN-gamma (pg/ml)	measured with Luminex assay	Measured after the first and second LPS-challenge (on day 7 and day 14)
Secondary	Change in lymphocyte surface antigen expression of PD-1 and IL7-RA		Measured after the first and second LPS-challenge (on day 7 and day 14)